Vertex Pharmaceuticals’ $10 Billion Crinetics Acquisition Sparks Investor Debate Over Valuation Amidst Lone Bidder Scenario
admin Boston, MA – Vertex Pharmaceuticals, a biotechnology giant primarily known for its groundbreaking cystic fibrosis...
biotech
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
A genetic medicine developed by Arrowhead Pharmaceuticals, known as plozasiran, has demonstrated compelling success in...
Crystalys Therapeutics Secures $130 Million Series B Funding to Accelerate Global Gout Treatment Program.
Emerging biotech firm Crystalys Therapeutics has announced a substantial $130 million Series B financing round,...
Novartis Navigates Critical Juncture with Q2 Sales Growth Amidst Looming Patent Cliffs and High-Stakes Pipeline Readouts
Novartis AG, the Swiss pharmaceutical giant, experienced a significant surge in its share price on...
Introducing the 2026 CRI Lloyd J. Old STARs: Five Scientists Shaping the Future of Cancer Immunotherapy
The Cancer Research Institute (CRI) has proudly announced the selection of its 2026 class of...
Novo Nordisk Files Lawsuit Against Eli Lilly Over "Deceptive" Obesity Drug Advertising Claims
In a significant escalation of the fiercely competitive market for GLP-1 agonist medications, Novo Nordisk...
Agios Pharmaceuticals Faces Setback as Tebapivat Study Fails, Highlighting Persistent Challenges in Sickle Cell Disease Drug Development
The clinical trial failure of Agios Pharmaceuticals’ investigational drug, tebapivat, marks a significant setback for...
From Protocol to Patient: Inside Clinical Supply
The global biopharmaceutical industry, a beacon of scientific innovation, faces an intricate journey in translating...
Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker
The biopharmaceutical sector is witnessing a transformative period marked by aggressive technological adoption, strategic mergers...
Tempus AI to Acquire Personalis in Strategic Move to Dominate Molecular Residual Disease Testing Market
Tempus AI has announced its definitive agreement to acquire Personalis, a leading innovator in molecular...
